Cyclic AMP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Galvani's hypothesis was proven in 1843 by Carlo Matteucci and Emil du Bois-Reymond with their discovery of the action potential. Du Bois-Reymond went on to devise a variety of electrical devices to stimulate and measure electrical activity in nerves and muscles, which he demonstrated to large audiences in Berlin, Paris, and London. In 1856, Guillaume Duchenne photographed electrotherapeutic stimulation of muscle contractions, stating that alternating current was superior to direct current in this stimulation.
In 2025, Medtronic was included in Forbes lists of America's Best Large Employers. In March 2026, Medtronic separated its diabetes business into MiniMed Group, Inc., which completed an initial public offering on March 9. Medtronic retained approximately 89.86% of MiniMed following the offering, while MiniMed became a separately publicly traded company on the Nasdaq. In September 2026, Medtronic launched an exchange offer as part of its planned separation of MiniMed. The offer covers up to 225,361,295 newly issued MiniMed common shares in exchange for Medtronic ordinary shares, representing approximately 80.1% of MiniMed's outstanding shares. If the exchange offer is oversubscribed, Medtronic intends to exchange additional shares of MiniMed representing its remaining interest, which would result in MiniMed becoming independent of Medtronic.The exchange offer is scheduled to expire on October 9, 2026, unless extended or terminated.
What Is Raynaud's Disease at the National Heart, Lung, and Blood Institute Questions and Answers About Raynaud's Phenomenon at the National Institutes of Health Bakst R, Merola JF, Franks AG, Sanchez M (October 2008). "Raynaud's Phenomenon: Pathogenesis and Management". Journal of the American Academy of Dermatology. 59 (4): 633–53. doi:10.1016/j.jaad.2008.06.004. PMID 18656283.
Sources: en.wikipedia.org
=== Removing plastics from oceans === One innovation of green nanotechnology that is currently under development are nanomachines modeled after a bacterium bioengineered to consume plastics, Ideonella sakaiensis. These nano-machines are able to decompose plastics dozens of times faster than the bioengineered bacteria not only because of their increased surface area but also because the energy released from decomposing the plastic is used to fuel the nano-machines.
6 July – Inverness, Skye and West Ross-shire becomes the final constituency to declare its election results, and sees the number of Liberal Democrat MPs rise to 72 after they defeat the SNP to win the seat. At his first press conference since taking office, Starmer announces that he wants to cut instances of re-offending to reduce the prison population. James Timpson is appointed as Minister of State for Prisons, Parole and Probation. Starmer announces the Rwanda asylum plan is "dead and buried". 7 July – Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. Jacqui Smith is appointed as Minister of State for Skills, Apprenticeships and Higher Education, while Douglas Alexander becomes Business Minister. The Starmer administration announces that the final two migrants due to be deported to Rwanda will be released on bail in the next few days; a further 218 are confirmed to have been released on bail by the Sunak administration before the election. Home Secretary Yvette Cooper outlines plans to establish a UK Border Security Command whose task it will be to reduce small boat crossings in the English Channel. 8 July – Chancellor Rachel Reeves announces plans to bring back compulsory housebuilding targets as part of plans to reboot the UK economy. Education Secretary Bridget Phillipson writes to all teachers in the education sector saying she wants to "reset the relationship" with the sector as part of plans to recruit an extra 6,500 teachers.
2-, alpha-, or α-amino acids have the generic formula H2NCHRCOOH in most cases, where R is an organic substituent known as a "side chain". Of the many hundreds of described amino acids, 22 are proteinogenic ("protein-building"). It is these 22 compounds that combine to give a vast array of peptides and proteins assembled by ribosomes. Non-proteinogenic amino acids may arise through nonribosomal peptide synthesis. Modified amino acids, by contrast, typically result from post-translational modification. Amino acids with the structure NH+3−CXY−CXY−CO−2, such as β-alanine, a component of carnosine and a few other peptides, are β-amino acids. Ones with the structure NH+3−CXY−CXY−CXY−CO−2 are γ-amino acids, and so on, where X and Y are two substituents (one of which is normally H).
Sources: en.wikipedia.org
== Function == So far, ArMs can catalyze planty of chemical reactions, such as: allylic alkylation, allylic amination, aldol reaction, alcohol oxidation, C-H activation, click reaction, catechol oxidation, CO2 reduction, cyclopropanation, Diels-Alder reaction, epoxidation, epoxide ring opening, Friedel-Crafts alkylation, hydrogenation, hydroformylation, Heck reaction, Metathesis, Michael addition, nitrite reduction, NO reduction, Suzuki reaction, Si-H insertion, polymerization (atom transfer radical polymerization), atom transfer radical cyclization (ATRC), radical fluorination and proton reduction.
=== Transport === Like most of northwest London, Brent is served extensively by the London Underground. 21 tube stations are located in Brent, all served by either the Metropolitan, Jubilee, Bakerloo or Piccadilly Lines. All of them are surface level, with the exception of Kilburn Park tube station in the southeast of the borough. This number is the second highest of all London boroughs behind Westminster, which has 32 stations within its boundaries. The numerous London Underground, London Overground and National Rail stations in the borough are:
=== Nutrition === Glutamine is the most abundant naturally occurring, nonessential amino acid in the human body, and one of the few amino acids that can directly cross the blood–brain barrier. Humans obtain glutamine through catabolism of proteins in foods they eat. In states where tissue is being built or repaired, like growth of babies, or healing from wounds or severe illness, glutamine becomes conditionally essential.
In the late 1950s, he studied the role of enzymes in brain function, believing that mental illness may be partly caused by enzyme dysfunction. In the 1960s, as part of his interest in the effects of nuclear weapons, he investigated the role of mutations in evolution, proposing with his student Emile Zuckerkandl, the molecular evolutionary clock, the idea that mutations in proteins and DNA accumulate at a constant rate over time .
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.